Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H25NO |
| Molecular Weight | 223.3544 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC\C=C\C=C\C(=O)NCC(C)C
InChI
InChIKey=MAGQQZHFHJDIRE-BNFZFUHLSA-N
InChI=1S/C14H25NO/c1-4-5-6-7-8-9-10-11-14(16)15-12-13(2)3/h8-11,13H,4-7,12H2,1-3H3,(H,15,16)/b9-8+,11-10+
| Molecular Formula | C14H25NO |
| Molecular Weight | 223.3544 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
Pellitorine is a major amide alkaloid, isolated from Piper longum, Zanthoxylum piperitum or heitzii, Anacyclus pyrethrum, Piper nigrum. Pellitorine can serve as an antagonist of the TRPV1 and may inhibit exovanilloid-induced pain. It exhibits anti-inflammatory activity via activating the Nrf2/HO-1 pathway. Pellitorine shows a good gut permeation and rapidly permeates the BBB once in the blood, indicating a possible role in the treatment of central nervous system diseases. Pellitorine, which was isolated from the roots of Piper nigrum, showed strong cytotoxic activities against HL60 and MCT-7 cancer cell lines. The drug possesses antithrombotic activities and offers bases for development of a novel anticoagulant.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27493960
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28899508 |
0.69 mM [IC50] | ||
Target ID: GO:0002537 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28185326 |
14.5 µM [IC50] | ||
Target ID: Acetyl-coenzyme A synthetase (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25422952 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28899508 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077682
Mice: 4.5 or 9 ug per animal
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28620299
Trans-pellitorine was found to suppress mean lipid accumulation in 3T3-L1 cells, when applied during differentiation and maturation, but also during maturation phase solely of 3T3-L1 cells in a concentration range between 1 nM and 1 uM by up to 8.84 or 7.49, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:30:23 GMT 2025
by
admin
on
Mon Mar 31 19:30:23 GMT 2025
|
| Record UNII |
8IS5231171
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1587
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
18836-52-7
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
DTXSID301019978
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
C008778
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
8IS5231171
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
5318516
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | |||
|
m8452
Created by
admin on Mon Mar 31 19:30:23 GMT 2025 , Edited by admin on Mon Mar 31 19:30:23 GMT 2025
|
PRIMARY | Merck Index |